Drug Trial Radar · NCT06742840
A Multiple Ascending Dose Trial of HRS-2129 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Dec 30, 2024
Primary completion
Jul 2, 2025
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-2129 in healthy subjects.
Conditions
- Pain
Interventions
HRS-2129Drug
HRS-2129.
HRS-2129 placeboDrug
HRS-2129 placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events (AEs)Time frame: From ICF signing date to Day 39.
- The incidence and severity of adverse events (AEs)Time frame: From ICF signing date to Day 41.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.